New Antibody Formats

Erscheinungsjahr 2022
ISBN: 978-0-323-99402-6
Verlag: William Andrew Publishing

Buch, Englisch, 212 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 450 g

New Antibody Formats, Volume 369 in the International Review of Cell and Molecular Biology serial, highlights new advances in the field with this new volume presenting interesting chapters on a variety of important topics, including Current innovative engineered antibodies, Advances in bispecific antibodies, Applications of trimerbodies for cancer immunotherapy, Multispecific mAb-Anticalin formats, New antibody formats to treat Lung Cancer, Immunocytokines: from bench to bedside, and Single domain antibodies in cancer.

Autoren/Hrsg.

Weitere Mitwirkende

Berraondo, Pedro

Fachgebiete

• Naturwissenschaften Biowissenschaften Zellbiologie
• Naturwissenschaften Biowissenschaften Molekularbiologie
• Naturwissenschaften Biowissenschaften Entwicklungsbiologie

Inhaltsverzeichnis

. Current innovative engineered antibodies Jose Yelamos 2. Opportunities and challenges of bi-specific antibodies Aina Segués, Shuyu Huang, Alice Sijts, Pedro Berraondo and Dietmar M. Zaiss 3. Applications of trimerbodies in cancer immunotherapy Marta Compte, Laura Sanz and Luis Álvarez-Vallina 4. Anticalin®-based therapeutics: Expanding new frontiers in drug development Aizea Morales-Kastresana, Martin Siegemund, Stefan Haak, Janet Peper-Gabriel, Vanessa Neiens and Christine Rothe 5. Overcoming the limitations of cytokines to improve cancer therapy Claudia Augusta Di Trani, Assunta Cirella, Leire Arrizabalaga, Myriam Fernandez-Sendin, Angela Bella, Fernando Aranda, Ignacio Melero and Pedro Berraondo 6. Emerging applications of nanobodies in cancer therapy Robin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, Thomas Ertveldt, Heleen Hanssens, Quentin Lecocq, Lukasz Mateusiak, Katty Zeven, Hana Valenta, Timo W.M. De Groof, Yannick De Vlaeminck, Ahmet Krasniqi, Kim De Veirman, Cleo Goyvaerts, Matthias D'Huyvetter, Sophie Hernot, Nick Devoogdt and Karine Breckpot

Über Autor(innen)

Berraondo, Pedro
Pedro Berraondo graduated in Pharmacy at the University of Navarra in 1999. In 2004 he obtained the Ph.D. at the same university. Next, he worked at the Pasteur Institute in Paris (France) under the supervision of Dr. Claude Leclerc, where he developed novel strategies in tumor immunotherapy within the European THERAVAC project. In February 2007, he joined the Immunology and Immunotherapy Program at the Cima Universidad de Navarra, where he leads the Cytokine-based Immunotherapy laboratory. He is co-inventor of ten patents and he is co-author of more than 140 publications, including publications in Nature, Nature Medicine, Nature Reviews Drug Discovery, Immunity, Cancer Discovery, and Cancer Cell. He was certified as a full professor in 2021 by AQU. He is co-director of the degree of expert in immunooncology at the Faculty of Medicine of the University of Navarra, and is in charge of the undergraduate course of macromolecular structure at the Faculty of Sciences of the University of Navarra. He is also the coordinator of the immuno-oncology work module at CIBERONC.